BOSTON, March 14 /PRNewswire/ -- AdipoGenix Inc., a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, today announced the achievement of its third milestone in the Company's drug discovery collaboration with Johnson & Johnson (J&J).
In November 2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix has utilized its proprietary human fat cell- based technologies for discovering compounds that reduce the fat content of human fat cells from J&J's compound collection. In addition, AdipoGenix has been characterizing the mechanisms of action and identifying molecular targets for the highest priority of the active compounds that were discovered. The milestone announced today was for the successful identification of the molecular target for one of J&J's active compounds that was discovered earlier in the collaboration. Financial details were not disclosed.
"This is the third milestone that we have achieved in our alliance with J&J, and this achievement provides further validation for our capability to discover compounds that have a beneficial effect on fat cells, and to define mechanisms and molecular targets for active compounds," said Ed Cannon, Ph.D., CEO of AdipoGenix.
Monique Berwaer, Principal Scientist and Metabolic Diseases Team Leader, Johnson & Johnson Pharmaceutical Research and Development commented, "AdipoGenix's human fat cell-based discovery technology is unique and we believe that treating obesity by targeting human fat with pharmaceuticals that reduce fat content is distinctive and an important new approach for combating the growing obesity epidemic."
AdipoGenix's core assets and capabilities include a proprietary and diverse collection of human fat cell precursors from all relevant fat deposits, a high-throughput discovery technology for differentiating these precursor cells to form mature human fat cells and identifying compounds that reduce the fat content of human fat cells, a portfolio of assays and pharmacologic tools to identify the mechanism of action and molecular targets for active compounds identified, and proprietary lead compounds. With this comprehensive approach, AdiopGenix has been able to rapidly identify non-toxic small molecule compounds that target the pathological tissue (fat) from the relevant organism (humans) and produce the desired therapeutic outcome (less fat).
About AdipoGenix Inc.
AdipoGenix is a Boston-based biopharmaceutical company developing pharmaceuticals that target human fat tissue to treat obesity and its co- morbidities, including diabetes and cardiovascular disease. Through its proprietary human fat cell-based technology, AdipoGenix identifies nontoxic, small molecule compounds that reduce the fat content in human fat tissue, which is expected to provide therapeutic benefit for these important diseases.
On the Net: http://www.AdipoGenix.com
Ed Cannon Kari Watson
President and CEO MacDougall Biomedical Communications
AdipoGenix Inc. (508) 647-0209
CONTACT: Ed Cannon, President and CEO of AdipoGenix Inc., +1-617-638-6394; or Kari Watson of MacDougall Biomedical Communications,+1-508-647-0209, email@example.com